We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

69 hedge funds and large institutions have $83.9M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

19% more funds holding

Funds holding: 58 → 69 (+11)

10% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $88.1M → $83.9M (-$4.14M)

Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
22
Reduced
20
Closed
5
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
-$70K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$18.6M
2
PA
Perceptive Advisors
New York
+$6.89M
3
Millennium Management
Millennium Management
New York
+$1.41M
4
CM
Crestline Management
Texas
+$799K
5
ECM
Endurant Capital Management
California
+$605K

Top Sellers

Rank Fund Capital Flow
1
ASP
Adams Street Partners
Illinois
-$4.27M
2
BlackRock
BlackRock
New York
-$2.47M
3
IHM
Iguana Healthcare Management
New York
-$870K
4
CS
Candriam SCA
Luxembourg
-$218K
5
PP
PDT Partners
New York
-$147K
Name Holding Trade Value Shares
Change 		Change in
Stake
Primecap Management
1
Primecap Management
California
$22.8M -$1.3K -300 -0%
BI
2
BVF Inc
California
$17.5M +$18.6M +4,271,289 New
PA
3
Perceptive Advisors
New York
$10.7M +$6.89M +1,582,608 +152%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.09M -$128K -29,417 -3%
Ameriprise
5
Ameriprise
Minnesota
$3.94M +$217K +49,953 +5%
Millennium Management
6
Millennium Management
New York
$2.23M +$1.41M +324,845 +149%
Renaissance Technologies
7
Renaissance Technologies
New York
$2.17M +$512K +117,700 +29%
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$2.14M – – –
ASP
9
Adams Street Partners
Illinois
$2.01M -$4.27M -982,354 -67%
CS
10
Candriam SCA
Luxembourg
$1.31M -$218K -50,000 -14%
DGI
11
Disciplined Growth Investors
Minnesota
$1.29M +$3K +690 +0.2%
CC
12
Cannell & Co
New York
$1.25M – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$1.15M +$535K +122,914 +78%
BlackRock
14
BlackRock
New York
$919K -$2.47M -568,181 -72%
First Eagle Investment Management
15
First Eagle Investment Management
New York
$900K – – –
CM
16
Crestline Management
Texas
$753K +$799K +183,687 New
Norges Bank
17
Norges Bank
Norway
$748K – – –
Bank of America
18
Bank of America
North Carolina
$628K +$1.35K +311 +0.2%
IHM
19
Iguana Healthcare Management
New York
$615K -$870K -200,000 -57%
ECM
20
Endurant Capital Management
California
$570K +$605K +139,100 New
Axa
21
Axa
France
$540K +$131K +30,006 +29%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$481K -$31.5K -7,239 -6%
BCM
23
Bridgeway Capital Management
Texas
$332K -$34.8K -8,000 -9%
AG
24
Algert Global
California
$266K +$283K +64,989 New
Two Sigma Investments
25
Two Sigma Investments
New York
$252K +$162K +37,205 +154%
1
2 3

OMED Hedge Fund Activity: Q4 2017 in Review

69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2017, worth a combined $83.9M — down 4.7% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new OMED positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $18.6M. The largest seller was Adams Street Partners, cutting an estimated $4.27M.

  • 69 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2017, up from 58 in Q3 2017.
  • Funds reported $83.9M of OncoMed Pharmaceuticals, Inc. stock for Q4 2017, down 4.7% quarter-over-quarter.
  • 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2017 was BVF Inc, an estimated $18.6M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2017 was Adams Street Partners, an estimated $4.27M sold.

Based on aggregated 13F filings for Q4 2017.